Morningstar - Spirit AeroSystems Holdings Inc. Class A (SPR) Morningstar | Placing Spirit AeroSystems Under Review. See Updated Analyst Note from 23 Apr 2019

Report

Morningstar

Keith Schoonmaker

EUR 850.00 For Business Accounts Only

Morningstar | Placing Spirit AeroSystems Under Review. See Updated Analyst Note from 23 Apr 2019

We are placing Spirit AeroSystems under review as we transfer coverage to a new analyst.

24/04/2019 3 EN

Underlying

Spirit AeroSystems Holdings Inc. Class A

Spirit AeroSystems Holdings is an independent non-Original Equipment Manufacturer commercial aerostructures designer and manufacturer. The company has three segments: Fuselage Systems, which includes development, production and marketing of forward, mid and rear fuselage sections and systems, and related spares and maintenance, repair, and overhaul (MRO) services; Propulsion Systems, which includes development, production and marketing of struts/pylons, nacelles, and related engine structural components, and related spares and MRO services; and Wing Systems, which includes development, production and marketing of wings and wing components, as well as related spares and MRO services.

See profile

US8485741099 New York Stock Exchange United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Keith Schoonmaker

Other Reports on these Companies

Vermilion Research

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 46.06

October 20, 2023 October 20, 2023 1 EN

Vermilion Research

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

EUR 46.06

September 22, 2022 September 22, 2022 1 EN

TheScreener

Increased risk weighs on SPIRIT AEROSYSTEMS, penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of SPIRIT AEROSYSTEMS (US), active in the Aerospace & Defense industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date April 5, 2022, the closing price was USD 46.20 and its target price was estimated at USD 35.94.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morningstar | Placing Spirit AeroSystems Under Review. See Updated Analyst Note from 23 Apr 2019

Vital Signs: Actionable charts

Vermilion Short Shots: Technically Vulnerable Stocks

Increased risk weighs on SPIRIT AEROSYSTEMS, penalising its rating down to Slightly Negative

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe